Crosstalk between epithelialmesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer

Masaki Shiota, Momoe Itsumi, Ario Takeuchi, Kenjiro Imada, Akira Yokomizo, Hidetoshi Kuruma, Junichi Inokuchi, Katsunori Tatsugami, Takeshi Uchiumi, Yoshinao Oda, Seiji Naito

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Although invasive and metastatic progression via the epithelial-mesenchymal transition (EMT) and acquisition of resistance to castration are both critical steps in prostate cancer, the molecular mechanism of this interaction remains unclear. In this study, we aimed to elucidate the interaction of signaling between castration resistance and EMT, and to apply this information to the development of a novel therapeutic concept using transforming growth factor-b (TGF-b) inhibitor SB525334 combined with androgen-deprivation therapy against prostate cancer usinganin vivomodel. This study revealedthat anEMTinducer (TGF-b) induced full-length androgen receptor (AR) and AR variant expression. In addition, a highly invasive clone showed augmented full-length AR and AR variant expression as well as acquisition of castration resistance. Conversely, full-length AR and AR as well as Twist1 and mesenchymal molecules variant expression were up-regulated in castration-resistant LNCaP xenograft. Finally, TGF-b inhibitor suppressed Twist1 and AR expression as well as prostate cancer growth combined with castration. Taken together, these results demonstrate that Twist1/AR signaling was augmented in castration resistant as well as mesenchymal-phenotype prostate cancer, indicating the molecular mechanism of mutual and functional crosstalk between EMTand castration resistance, which may play a crucial role in prostate carcinogenesis and progression.

Original languageEnglish
Pages (from-to)889-900
Number of pages12
JournalEndocrine-Related Cancer
Volume22
Issue number6
DOIs
Publication statusPublished - Dec 2015

Fingerprint

Castration
Androgen Receptors
Prostatic Neoplasms
Transforming Growth Factors
Epithelial-Mesenchymal Transition
Heterografts
Androgens
Prostate
Carcinogenesis
Clone Cells
Phenotype
Therapeutics
Growth

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Cite this

@article{7bba568097a54fe68b22a8caf64dc854,
title = "Crosstalk between epithelialmesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer",
abstract = "Although invasive and metastatic progression via the epithelial-mesenchymal transition (EMT) and acquisition of resistance to castration are both critical steps in prostate cancer, the molecular mechanism of this interaction remains unclear. In this study, we aimed to elucidate the interaction of signaling between castration resistance and EMT, and to apply this information to the development of a novel therapeutic concept using transforming growth factor-b (TGF-b) inhibitor SB525334 combined with androgen-deprivation therapy against prostate cancer usinganin vivomodel. This study revealedthat anEMTinducer (TGF-b) induced full-length androgen receptor (AR) and AR variant expression. In addition, a highly invasive clone showed augmented full-length AR and AR variant expression as well as acquisition of castration resistance. Conversely, full-length AR and AR as well as Twist1 and mesenchymal molecules variant expression were up-regulated in castration-resistant LNCaP xenograft. Finally, TGF-b inhibitor suppressed Twist1 and AR expression as well as prostate cancer growth combined with castration. Taken together, these results demonstrate that Twist1/AR signaling was augmented in castration resistant as well as mesenchymal-phenotype prostate cancer, indicating the molecular mechanism of mutual and functional crosstalk between EMTand castration resistance, which may play a crucial role in prostate carcinogenesis and progression.",
author = "Masaki Shiota and Momoe Itsumi and Ario Takeuchi and Kenjiro Imada and Akira Yokomizo and Hidetoshi Kuruma and Junichi Inokuchi and Katsunori Tatsugami and Takeshi Uchiumi and Yoshinao Oda and Seiji Naito",
year = "2015",
month = "12",
doi = "10.1530/ERC-15-0225",
language = "English",
volume = "22",
pages = "889--900",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "Society for Endocrinology",
number = "6",

}

TY - JOUR

T1 - Crosstalk between epithelialmesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer

AU - Shiota, Masaki

AU - Itsumi, Momoe

AU - Takeuchi, Ario

AU - Imada, Kenjiro

AU - Yokomizo, Akira

AU - Kuruma, Hidetoshi

AU - Inokuchi, Junichi

AU - Tatsugami, Katsunori

AU - Uchiumi, Takeshi

AU - Oda, Yoshinao

AU - Naito, Seiji

PY - 2015/12

Y1 - 2015/12

N2 - Although invasive and metastatic progression via the epithelial-mesenchymal transition (EMT) and acquisition of resistance to castration are both critical steps in prostate cancer, the molecular mechanism of this interaction remains unclear. In this study, we aimed to elucidate the interaction of signaling between castration resistance and EMT, and to apply this information to the development of a novel therapeutic concept using transforming growth factor-b (TGF-b) inhibitor SB525334 combined with androgen-deprivation therapy against prostate cancer usinganin vivomodel. This study revealedthat anEMTinducer (TGF-b) induced full-length androgen receptor (AR) and AR variant expression. In addition, a highly invasive clone showed augmented full-length AR and AR variant expression as well as acquisition of castration resistance. Conversely, full-length AR and AR as well as Twist1 and mesenchymal molecules variant expression were up-regulated in castration-resistant LNCaP xenograft. Finally, TGF-b inhibitor suppressed Twist1 and AR expression as well as prostate cancer growth combined with castration. Taken together, these results demonstrate that Twist1/AR signaling was augmented in castration resistant as well as mesenchymal-phenotype prostate cancer, indicating the molecular mechanism of mutual and functional crosstalk between EMTand castration resistance, which may play a crucial role in prostate carcinogenesis and progression.

AB - Although invasive and metastatic progression via the epithelial-mesenchymal transition (EMT) and acquisition of resistance to castration are both critical steps in prostate cancer, the molecular mechanism of this interaction remains unclear. In this study, we aimed to elucidate the interaction of signaling between castration resistance and EMT, and to apply this information to the development of a novel therapeutic concept using transforming growth factor-b (TGF-b) inhibitor SB525334 combined with androgen-deprivation therapy against prostate cancer usinganin vivomodel. This study revealedthat anEMTinducer (TGF-b) induced full-length androgen receptor (AR) and AR variant expression. In addition, a highly invasive clone showed augmented full-length AR and AR variant expression as well as acquisition of castration resistance. Conversely, full-length AR and AR as well as Twist1 and mesenchymal molecules variant expression were up-regulated in castration-resistant LNCaP xenograft. Finally, TGF-b inhibitor suppressed Twist1 and AR expression as well as prostate cancer growth combined with castration. Taken together, these results demonstrate that Twist1/AR signaling was augmented in castration resistant as well as mesenchymal-phenotype prostate cancer, indicating the molecular mechanism of mutual and functional crosstalk between EMTand castration resistance, which may play a crucial role in prostate carcinogenesis and progression.

UR - http://www.scopus.com/inward/record.url?scp=84948159052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948159052&partnerID=8YFLogxK

U2 - 10.1530/ERC-15-0225

DO - 10.1530/ERC-15-0225

M3 - Article

C2 - 26311513

AN - SCOPUS:84948159052

VL - 22

SP - 889

EP - 900

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 6

ER -